Palsonify Logo

Now FDA Approved

GO TO PALSONIFY.COM
Palsonify Logo

Now FDA Approved

GO TO PALSONIFY.COM

News & Events

Show:
January 28, 2015

Crinetics Pharmaceuticals Awarded $1.5MM NIH Phase-II SBIR Grant to Develop Kisspeptin Receptor Antagonists for PCOS and Other Women’s Health Diseases

SAN DIEGO — January 28, 2015 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a $1. 5 MM Phase II Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) for the development of orally-available, small molecule kisspeptin receptor antagonists to treat polycystic ovary syndrome (PCOS) and other women’s health disorders. “PCOS is so prevalent, yet inadequately treated in most patients.

READ MORE
April 28, 2014

Crinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases

SAN DIEGO — April 28, 2014 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to explore the use of its oral, small molecule somatostatin receptor agonist drug candidates for the treatment of ophthalmic diseases such as macular degeneration and diabetic retinopathy. Currently, it is estimated that 11 million Americans suffer from age-related macular degeneration (AMD) – this number is expected to double in the next generation. Worldwide, the global diabetes epidemic has pushed the number of people suffering from diabetic retinopathy to an estimated 93 million.

READ MORE
September 13, 2013

Crinetics Pharmaceuticals Awarded NIH Phase-II SBIR Grant to Develop Drugs for Pituitary Tumors

SAN DIEGO — September 3, 2013 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a $2. 2MM Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop novel drugs for the treatment of pituitary tumors. These tumors produce excess growth hormone resulting in a range of symptoms that can include gigantism, excess soft tissue growth, arthritis, hypertension, diabetes, heart failure, kidney failure, and vision loss, a condition called acromegaly.

READ MORE
February 7, 2009

Crinetics Pharmaceuticals Awarded National Institutes of Health Small Business Innovative Research Grant to Develop GPCR Biosensors for Drug Discovery

Crinetics Pharmaceuticals announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop G protein-coupled receptor (GPCR) biosensors for drug discovery applications. The grant supports the Company’s effort to expand this cutting-edge research tool to drug targets addressing important unmet medical needs and adapt the technology to formats suitable for routine use in GPCR drug discovery. GPCR biosensors are one component of the company’s emerging GPCR Dynamics assay platform.

READ MORE